| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Award
It has been six years since the council of the Society of Leukocyte Biology initiated cash awards in honor of Dolph Adams. The $1000 award, which was established to recognize the most highly cited research paper and review article published in the journal, is based on the number of citations over the last 5 years, and gauges the effect of the papers on the scientific community. The prize is awarded to the corresponding authors, who decide how to share it with their coauthors.
Last year’s winners were Combadiere et al. for "Cloning and functional expression of CC-CKR5" (J. Leukoc. Biol. 60: 147–152, 1996) and Matthew Sweet and David Hume for their review of "Endotoxin signal transduction in macrophages" (J. Leukoc. Biol. 60: 8–26, 1996).
For the year 2001, the most-cited research paper, with 75 citations
from 1996-2000, was by William J. Karpus and Kevin J. Kennedy from
Northwestern University Medical School entitled, MIP-1
and MCP-1
differentially regulate acute and relapsing EAE as well as TH1/TH2
lymphocyte differentiation (J. Leukoc. Biol. 62:
681–687, 1997).
Dr. Karpus hypothesized that chemokines might be involved in the
migration of mononuclear cells into central nervous system (CNS) sites
of experimental allergic encephalomyelitis (EAE). He and Kevin Kennedy
identified MIP-1 alpha in EAE lesions. To determine if desensitization
of T cell chemokine receptor function could inhibit EAE pathogenesis,
MIP-1alpha or MCP-1 was added to T cell activation cultures. However,
when they preincubated autoreactive T cells with MIP-1alpha or MCP-1,
only the MIP-1 pretreated T cells transferred EAE, which the MCP-1 T
cells failed to adoptively transfer EAE. This led them to show that
MCP-1 stimulated T cells produce IL-4 and differentiate into TH2
cytokine producers, while MIP-1alpha induced low levels of
interferon-gamma and favored TH1 differentiation. Their article is
therefore highly cited based on the observation that chemokines can
have such pivotal effects on T cell differentiation. Dr. Karpus, who is
now an associate professor in the Department of Pathology at
Northwestern University Medical School, has continued his studies of
the role of chemokines and cytokines in demyelinatine diseases of the
CNS. Kevin Kennedy, after six productive years with Dr. Karpus, is now
a senior research technologist at the University of Chicago Medical
School.
We also recognize and honor the five next most-cited research articles from 1996–2000, with 70 to 53 citations:
Kiertscher, S. M. and Roth, M. D. Human CD14+
leukocytes acquire the phenotype and function of antigen-presenting
dendritic cells when cultured in GM-CSF and IL-4. J. Leukoc.
Biol. 59: 208–218, 1996.
Manickan, E., Kanangat, S., Rouse, R. J., Yu, Z. and Rouse,
B. T. Enhancement of immune response to naked DNA vaccine by
immunization with transfected dendritic cells. J. Leukoc.
Biol. 61: 125–132, 1997.
Xu, L. L., Warren, M. K., Rose, W. L., Gong, W., and
Wang, J. M.: Human recombinant monocyte chemotactic protein and
other C-C chemokines bind and induce directional migration of dendritic
cells in vitro. J. Leukoc. Biol. 60: 365–371, 1996.
Rajora, N., Ceriani, G., Catania, A., Star, R.A., Murphy, M.T., and
Lipton, J.M. alpha-MSH production, receptors, and influence on
neopterin in a human monocyte/macrophage cell line. J. Leukoc. Biol. 59: 248–253, 1996.
Dvorak, M., Kohn, S., Morgan, E.S., Fox, P., Nagy, J.A., and
Dvorak, H.F.: The vesico-vacuolar organelle (VVO): a distinct
endothelial cell structure that provides a transcellular pathway for
macromolecular extravasation. J. Leukoc. Biol. 59:
100–115, 1996.
John Lee and Peter Young wrote the award-winning review (161 citations), Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms (J. Leukoc. Biol. 59: 152–157, 1996), which was presented at the International Symposium of Molecular Cell Biology of Macrophages in Inuyama, Japan, 1995.
Drs. Lee and Young collaborated while at SmithKline Beecham on studies of interleukin-1 (IL-1). They were interested in identifying small molecule antagonists of IL-1, but failed—like everyone else. Rather than give up, they pursued inhibitors of IL-1 production. Although these inhibitors were thought to affect arachidonate metabolism, the most potent of these inhibitors failed to block the 5-lipoxygenase or cyclooxygenase pathways. This led them to tackle the arduous task of identifying the molecular target of the inhibitor, which they named CSBP or cytokine suppressive binding protein. Purification and sequencing of CSBP enabled cloning of a novel human protein kinase and revealed it to be identical to the concomitantly discovered murine p38, a member of the stress-activated protein kinases. One of the earliest inhibitors of p38, SB203580, is still in the highest demand by many research labs, and derivatives are undergoing clinical evaluation as inhibitors of IL-1 and TNF production in inflammatory conditions such as rheumatoid arthritis. Dr. Lee is still working at what is now GlaxoSmithKline, where he is a department head of high throughput biology. Dr. Young is Director of Cardiovascular Disease Research at Bristol Myers Squibb and studies coagulation, dyslipidemia, and obesity.
The five runners-up in the review category for 1996–2000 with 136-104 citations were:
DeLeo, F. R. and Quinn, M. T. Assembly of the phagocyte
NADPH oxidase: molecular interactions of oxidase proteins.J. Leukoc. Biol. 60: 677–691, 1996.
O’Neill, L. A. and Greene, C. Signal transduction pathways
activated by the IL-1 receptor family: ancient signaling machinery in
mammals, insects, and plants. J. Leukoc. Biol. 63:
650–657, 1998 (a meeting overview).
Farber, J. M. Mig and IP-10: CXC chemokines that target
lymphocytes. J. Leukoc. Biol. 61: 246–257, 1997.
Darnay, B. G. and Aggarwal, B. B. Early events of TNF
signaling: a story of associations and dissociations. J. Leukoc. Biol. 61: 559–566, 1997 (a meeting overview).
McConkey, D. J. and Orrenius, S. The role of calcium in the
regulation of apoptosis. J. Leukoc. Biol. 59: 775–783,
1996 (a meeting overview).
It is significant that in addition to the winning review, three of the five most highly cited papers in this category were also meeting overviews, supporting the merit of inviting this type of article for publication in the journal.
The Journal
Overall, the state of the journal continues to improve. The citation index at 4.342 is slightly higher for citations in 2000 than to articles published in 1999 and 1998. The journal ranks 7th among 60 hematology journals and 7th of 116 immunology journals that predominantly publish original refereed papers, rather than reviews. We definitely fulfill a need in the scientific community and have maintained our level of citations despite the introduction of high-profile immunological journals, such as Nature Immunology, and continued improvements by the established journals. This view is supported by an increase of about 20% in the number of papers submitted to JLB and by my editors who tell me that the quality of the submitted papers has progressively improved over the past 5 years. We continue to publish about 25 invited and several unsolicited reviews annually, as so ably selected by our associate editor Dr. Craig Reynolds, and publish invited meeting overviews from 2-3 meetings per year.
We began an on-line review system with EJournal Press last May. After some initial—and painful—shortcomings, the system is working beautifully. We have about 7 months of data that can be evaluated and have cut our mailing costs by about 90%. There has been a decrease of about 33% in the length of review time, from 6 to 4 weeks. Generally, editors, reviewers, and authors have been pleased with the result. We will be better able to evaluate the system by the end of next year. Although statistics are still not complete, we are accepting about 40% of submitted papers, which perhaps reflects either the higher quality of the paper or editorial "battle fatigue." Even with this higher rate of acceptance, however, we have exceeded the 2000-page limit by only 5%. We will continue to do our best to provide rigorous, constructively critical, and timely reviews and to reject those papers that are not novel, not important, or not definitive.
Plans are in the works for posting papers online the day after they are accepted and 3 months before the print version comes out. We plan to double the page charges for those exceeding the 8-page limit in order to encourage authors to be more succinct. We will also double the page charges for printed pages for corresponding authors who are not members of the Society of Leukocyte Biology, giving them the option of paying or joining the society when their paper is accepted. We hope these minor changes will enable us to cover the ever-increasing costs of publishing JLB.
Please provide feedback and suggestions. Your input is essential to the continued improvement of the journal.
Related Articles
J. Leukoc. Biol. 1998 63: 650-657.
J. Leukoc. Biol. 1997 62: 681-687.
J. Leukoc. Biol. 1997 61: 559-566.
J. Leukoc. Biol. 1997 61: 246-257.
J. Leukoc. Biol. 1997 61: 125-132.
J. Leukoc. Biol. 1996 60: 677-691.
J. Leukoc. Biol. 1996 60: 365-371.
J. Leukoc. Biol. 1996 60: 147-152.
J. Leukoc. Biol. 1996 59: 775-783.
J. Leukoc. Biol. 1996 59: 152-157.
J. Leukoc. Biol. 1996 59: 208-218.
J. Leukoc. Biol. 1996 59: 248-253.
J. Leukoc. Biol. 1996 59: 100-115.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
